Haemonetics Corp. VP Sells $167,200 in Stock (HAE)
Haemonetics Corp. (NYSE:HAE) VP Susan M. Hanlon sold 4,000 shares of the company’s stock on the open market in a transaction dated Friday, January 10th. The stock was sold at an average price of $41.80, for a total transaction of $167,200.00. Following the completion of the sale, the vice president now directly owns 16,905 shares of the company’s stock, valued at approximately $706,629. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
HAE has been the subject of a number of recent research reports. Analysts at Benchmark Co. downgraded shares of Haemonetics Corp. from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, December 31st. They now have a $46.00 price target on the stock, down previously from $49.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Haemonetics Corp. in a research note to investors on Friday, December 27th. They now have a $45.00 price target on the stock. Finally, analysts at UBS AG initiated coverage on shares of Haemonetics Corp. in a research note to investors on Tuesday, December 17th. They set a “sell” rating and a $39.00 price target on the stock. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. Haemonetics Corp. currently has a consensus rating of “Hold” and a consensus price target of $44.83.
Haemonetics Corp. (NYSE:HAE) traded up 1.25% during mid-day trading on Tuesday, hitting $42.97. The stock had a trading volume of 248,378 shares. Haemonetics Corp. has a one year low of $37.71 and a one year high of $45.90. The stock has a 50-day moving average of $42.47 and a 200-day moving average of $41.56. The company has a market cap of $2.214 billion and a P/E ratio of 70.73.
Haemonetics Corp. (NYSE:HAE) last released its earnings data on Monday, October 28th. The company reported $0.66 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.57 by $0.09. The company had revenue of $235.80 million for the quarter, compared to the consensus estimate of $239.51 million. During the same quarter last year, the company posted $0.90 earnings per share. Haemonetics Corp.’s revenue was up 7.7% compared to the same quarter last year. On average, analysts predict that Haemonetics Corp. will post $2.35 earnings per share for the current fiscal year.
Haemonetics Corporation is a healthcare company. The Company is engaged developing and manufacturing automated blood component collection devices and surgical blood salvage devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.